Antiviral drug

Global Clinical Trials Report: COVID-19 Special Edition - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 14, 2020
Infectious diseases, Health, Clinical trials, Health, Viruses, Coronaviridae, Pneumonia, Severe acute respiratory syndrome, Zoonoses, Clinical trial, Coronavirus, Antiviral drug

The "Clinical Trial Report COVID-19 Special Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Trial Report COVID-19 Special Edition" report has been added to ResearchAndMarkets.com's offering.
  • The cataclysm caused by the COVID-19 pandemic has impacted on clinical trials in terms of alternatives for study participants, enhanced operational and financial support for progressively more complex trial protocol designs, and greater collaboration among sponsors.
  • Therefore, presented here is a timely summarised report of new candidate antiviral and vaccine therapies undergoing clinical trials worldwide in the pursuit of gaining regulatory approval for treatment and/or prophylaxis against SARS-CoV-2 coronavirus infection.

Senzer to Create Targeted Anti-viral Treatments for COVID-19

Retrieved on: 
Thursday, May 14, 2020
Pharmacology, Health, Routes of administration, Medication, Pharmaceutical industry, Respiratory tract, Antiviral drug, Dosage forms

LONDON, May 14, 2020 /PRNewswire/ -- Senzer Pharmaceuticals, a UK company involved in the development, manufacture and licencing of pioneering respiratory products for pharmaceutical formulations, has launched a Critical Care Division, which will utilise its expertise in respiratory pharmaceuticals to create targeted anti-viral treatments for COVID-19.

Key Points: 
  • LONDON, May 14, 2020 /PRNewswire/ -- Senzer Pharmaceuticals, a UK company involved in the development, manufacture and licencing of pioneering respiratory products for pharmaceutical formulations, has launched a Critical Care Division, which will utilise its expertise in respiratory pharmaceuticals to create targeted anti-viral treatments for COVID-19.
  • The targeted delivery of anti-virals to where the viral load from COVID-19 is heaviest, the respiratory tract, is at the centre of Senzer's Critical Care strategy.
  • The targeted delivery of actives through inhalation offers potential advantages over oral intake.
  • Senzer's platform is based around a patented device that allows swift and effective inhaled delivery of medicines, in a consistent dose-controlled presentation.

Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities

Retrieved on: 
Monday, May 11, 2020
Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Ebola, Chemical compounds, Favipiravir, Hydroxyarenes, Organofluorides, Pyrazines, Organic compounds, Chemistry, Antivirals, Antiviral drug

With FFTC providing support through donated drug product, the phase 2 study will be conducted at long-term care facilities in Ontario.

Key Points: 
  • With FFTC providing support through donated drug product, the phase 2 study will be conducted at long-term care facilities in Ontario.
  • Appili has filed the clinical trial application (CTA) with Health Canada and expects to initiate the trial as soon as possible following receipt of regulatory clearance.
  • This program illustrates our commitment to leverage our relationships and expertise to do the right thing for patients and public health.
  • Favipiravir is a broad-spectrum antiviral developed by FFTC and approved in Japan under the brand name Avigan.

Global Market for Antiviral Drugs: Recent Developments by Key Market Participants Including Gilead Sciences, AbbVie and Cipla Inc. - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020
Infectious diseases, Pharmaceutical, Health, Antiviral drug, Biocides, Biology, Life sciences, Biotron Limited

The global antiviral drugs market size is expected to reach USD 46.9 billion by 2027.

Key Points: 
  • The global antiviral drugs market size is expected to reach USD 46.9 billion by 2027.
  • This, in turn, will drive the demand for antiviral drugs, which can be used to treat a range of viral infections.
  • The presence of pipeline antiviral products for HIV therapeutics is anticipated to drive the market over the forecast period.
  • Recent developments & impact analysis, by key market participants

DongWha Pharm’s DW2008 Shows Excellent Antiviral Activity Against COVID-19

Retrieved on: 
Wednesday, May 6, 2020
Infectious diseases, Pharmaceutical, Health, Clinical trials, Organic compounds, Chemical compounds, Drugs, Antivirals, RTT, Antiviral drug, Biocides, TIGIT, Chloroquine, Remdesivir

In vitro antiviral experiments performed at the Institut Pasteur Korea against COVID-19 demonstrated that DW2008 had 1.7, 3.8, and 4.7 times higher antiviral activity compared to chloroquine, remdesivir, and Kaletra respectively.

Key Points: 
  • In vitro antiviral experiments performed at the Institut Pasteur Korea against COVID-19 demonstrated that DW2008 had 1.7, 3.8, and 4.7 times higher antiviral activity compared to chloroquine, remdesivir, and Kaletra respectively.
  • In addition to antiviral effects, DW2008 also inhibits TIGIT, one of the second- generation immune checkpoint proteins, which was recently reported to diminish host antiviral immunity to COVID-19.
  • Its excellent tolerability and desirable pharmacokinetic properties were also confirmed in humans, during its phase 1 clinical studies.
  • Currently, DongWha Pharm has applied for phase 2 clinical trials for treating asthma patients with DW2008.

EQS-News: Rapid Nutrition to Launch New Oral Anti-Viral Therapy to combat Influenza & Common Cold

Retrieved on: 
Tuesday, May 5, 2020
Articles, Health, Medical specialties, RTT, Influenza, Antiviral drug, Nutrition

Brisbane, Australia -Rapid Nutrition plc (SW: RAP , OTCQB: RPNRF ) will launch a new oral anti-viral treatment called Azurene that is designed to combat influenza and the common cold in humans.

Key Points: 
  • Brisbane, Australia -Rapid Nutrition plc (SW: RAP , OTCQB: RPNRF ) will launch a new oral anti-viral treatment called Azurene that is designed to combat influenza and the common cold in humans.
  • A natural healthcare company focused on sports nutrition, diet management and life sciences products with extensive worldwide distribution.
  • "It is a rare opportunity to have the ability to combat influenza as well as the common cold with a new anti-viral therapy, and we are thrilled to introduce Azurene to a broader global market," said Rapid Nutrition CEO Simon St.
  • Rapid Nutrition is a natural healthcare company focused on the research, development and production of a range of life science products.

Growing Number of Collaborations in U.S. Public & Private Sectors Fueling Positive Coronavirus Vaccine Developments

Retrieved on: 
Monday, May 4, 2020
Antiviral drug, Biocides, Animal virology, Vaccine, Coronavirus, Biology, Branches of biology, Medical specialties

Every day there are new updated reports and articles describing new efforts and collaborations to find the solutions.

Key Points: 
  • Every day there are new updated reports and articles describing new efforts and collaborations to find the solutions.
  • They show that scientists around the world are working on potential treatments and vaccines for the new coronavirus disease.
  • Lee says antivirals work better if you administer them sooner, "before the virus has a chance to multiply significantly.
  • However, he (said) that "antivirals are likely to be developed and approved before a vaccine, which typically takes longer and are centered around existing drugs."

Growing Number of Collaborations in U.S. Public & Private Sectors Fueling Positive Coronavirus Vaccine Developments

Retrieved on: 
Monday, May 4, 2020
Antiviral drug, Biocides, Animal virology, Vaccine, Coronavirus, Biology, Branches of biology, Medical specialties

Every day there are new updated reports and articles describing new efforts and collaborations to find the solutions.

Key Points: 
  • Every day there are new updated reports and articles describing new efforts and collaborations to find the solutions.
  • They show that scientists around the world are working on potential treatments and vaccines for the new coronavirus disease.
  • Lee says antivirals work better if you administer them sooner, "before the virus has a chance to multiply significantly.
  • However, he (said) that "antivirals are likely to be developed and approved before a vaccine, which typically takes longer and are centered around existing drugs."

ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal

Retrieved on: 
Thursday, April 30, 2020
Organic compounds, Antivirals, Chemistry, Nitriles, Nucleotides, Organophosphates, Remdesivir, Antiviral drug, Functional groups

The concentrations of merimepodib and remdesivir used in this article are achievable by our oral merimepodib and intravenous remdesivir.

Key Points: 
  • The concentrations of merimepodib and remdesivir used in this article are achievable by our oral merimepodib and intravenous remdesivir.
  • Merimepodib, a broad-spectrum anti-viral candidate, demonstrated strong activity against COVID-19 in cell cultures in laboratory testing.
  • Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against COVID-19 in cell cultures.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference

Retrieved on: 
Tuesday, April 28, 2020
Medical specialties, Antiviral drug, Biocides, Medicine, Influenza, Infection, Health

Cidara is developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections.

Key Points: 
  • Cidara is developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections.
  • The Companys portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to therapies targeting influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform.
  • Cidara is headquartered in San Diego, California.
  • For more information, please visit www.cidara.com.